October 12, 2026
On October 5, Curaleaf raised its offer for Aurora Cannabis to an implied US$5.00 a share, up 25% from the original US$4.00. Aurora told shareholders to keep waiting. Then, late last week, the trade outlet Cultivated reported that Aurora has been in merger talks with Organigram Global for "the past few weeks," according to MMJDaily. Neither Aurora nor Organigram has confirmed the talks.
Curaleaf's statement on the report was "We are outraged, and Aurora shareholders should be too." The Curaleaf-Aurora takeover now has a possible second suitor, and Aurora's board has about a week and a half left to answer the new bid.
Curaleaf filed its notice of variation on October 6. The new terms, per Aurora share:
| Original (Aug. 18) | Amended (Oct. 6) | |
|---|---|---|
| Cash | US$0.75 | US$1.00 |
| Curaleaf shares | 0.3463 | 0.4013 |
| Implied value | ~US$4.00 | US$5.00 |
| Cap | US$5.00 | US$6.00 |
| Expiry | Dec. 1, 5:00 p.m. MT | Dec. 4, 11:59 p.m. MT |
The US$5.00 figure is based on Curaleaf's C$14.21 close on October 2. Most of the payment is still Curaleaf stock, so the value moves with Curaleaf's share price until the cap kicks in. If Curaleaf's 20-day average price tops C$17.76, the exchange ratio shrinks. Curaleaf puts the premium at 86% over Aurora's US$2.75 average before the first bid.
The filing also goes partway toward what Aurora asked the Alberta Securities Commission for in September. Curaleaf added pro forma financial statements for the combined company and moved the expiry three days, to December 4. Aurora had asked for a full 105-day deposit period starting after the fixes, which would have pushed the deadline into 2027. Curaleaf said it disagrees that the pro formas were required and provided them anyway. Aurora's October 5 release said its application "delivered results for shareholders." Neither company has disclosed a commission ruling on either side's application.
The combined company would have had US$1.50 billion in revenue in 2025 and US$775 million in the first half of 2026, according to the unaudited pro forma statements in the variation notice. Curaleaf built them from Aurora's public filings and says it has not verified them, because Aurora still hasn't given it diligence access. Curaleaf's release projects at least US$40 million in annual cost savings from combining the two companies.
To succeed, the bid needs more than 50% of Aurora's shares held by independent holders. That condition can't be waived.
Aurora's board formed a special committee of independent directors to review the amended bid. "The filing of a revised Hostile Bid is simply the next step in the process, not a deadline to make a decision," CEO Miguel Martin said in Aurora's October 6 release. The take-no-action advice from September 2 stands.
Aurora's October 5 release said the board will announce its recommendation by news release and directors' circular within 15 days. Counting from the October 6 filing, that puts the answer around October 21.
The Organigram talks are unconfirmed, and no terms have been reported. Curaleaf is acting as if the report is accurate. Its statement to MMJDaily called itself "the world's largest cannabis company (market cap: $2.6 billion)" and said it is "being denied customary due diligence access" while a much smaller Canadian company appears to be welcome. "If value is truly the objective, shareholders should demand that Curaleaf be invited into Aurora's process," the company said.
If the talks are real, Aurora would be doing what targets of hostile bids often do: looking for a friendlier partner so shareholders have a second option. Curaleaf would then be competing with a Canadian producer for a Canadian company, with its own stock as most of the currency.
Watch the cost savings. A US$40 million savings target usually comes from purchasing, overhead, and duplicate contracts. Aurora's business is in Canada and international medical markets, so most of the overlap is outside U.S. retail. U.S. vendors should still expect Curaleaf to look harder at what it spends if the deal goes through.
This runs into December at least. The offer is open until December 4 and the board hasn't made a recommendation yet. If a rival offer appears, Curaleaf management could be focused on Canada through year-end. The November 3 third-quarter call is the next chance to hear how much attention its U.S. stores are getting.
Curaleaf isn't your only buyer. In most of its markets, Curaleaf competes with independent dispensaries that are dealing with no takeover at all.
What is Curaleaf offering for Aurora Cannabis? US$1.00 in cash plus 0.4013 Curaleaf shares per Aurora share, an implied US$5.00 based on Curaleaf's October 2 close, capped at US$6.00. The offer expires December 4, 2026.
Has Aurora accepted Curaleaf's offer? No. Aurora's special committee is reviewing the amended bid, and the board has told shareholders to take no action until it issues a recommendation.
Is Organigram bidding for Aurora? Cultivated reported that the two companies have been in merger talks. Neither has confirmed it, and no offer has been announced.
Did the Alberta Securities Commission rule on the bid? Neither company has disclosed a ruling. Curaleaf addressed Aurora's main complaints by adding pro forma financial statements and extending the expiry.
Curaleaf's leadership will be busy with the Aurora bid until at least December. The independent stores competing with it are not. See verified, owner-level contacts for independent dispensaries in six states, refreshed weekly. Free preview at holdenleads.com.
Holden Leads
Dispensaries, cultivators, manufacturers, distributors and testing labs, cross-referenced weekly against official state regulatory databases and enriched with phone numbers, emails, websites, and social profiles. Stop manually hunting for contact info. Get the full list today.